Answers are grounded in this paper and cite their sources.
Analysis suggests low gene status of BMP6 and OLFM1 predicts recurrence-free survival in early-stage non-small cell lung cancer, indicating a need for personalized treatment.
While pathological stage I (pStage I) non-small cell lung cancer (NSCLC) has a good prognosis, some patients experience disease recurrence. Identification of prognostic markers for pStage I NSCLC may facilitate personalized perioperative treatment by expanding the candidates for adjuvant treatment. NSCLC patients with ground-glass opacity have excellent survival outcomes. Therefore, in this study, we explored prognostic biomarkers in pure solid non-squamous NSCLC. We focused on non-squamous NSCLC because the gene expression status is distinct from that of squamous cell carcinomas. RNA sequencing was performed on frozen tumor specimens from 33 non-squamous NSCLC patients with disease recurrence (recurrence group) and 33 counterparts (control group) extracted from patients without disease recurrence using propensity score matching (Cohort 1). The candidate genes were further refined using an independent real-world Cohort 2a (N = 125) and validated in The Cancer Genome Atlas cohort. Through the analysis of Cohort 1 and Cohort 2a, we found that low expression of six genes (BMP6, KCNK3, NFASC, OLFM1, PEG3, and TNXB) was associated with disease recurrence. The prognostic impact of the six genes was confirmed using The Cancer Genome Atlas lung adenocarcinoma database. Multivariable proportional hazard analysis using the Cohort 2a dataset revealed that the combination of BMP6 and OLFM1 status predicted recurrence-free survival. In conclusion, we found that low BMP6/OLFM1 gene status is a potential biomarker to identify high-risk pStage I pure solid non-squamous NSCLC patients after pulmonary resection.
No takes yet. Share an insight, caveat, or question.
Suda et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: